Bio-Techne Corp [TECH] stock prices are up 0.30% to $53.15 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TECH shares have gain 3.69% over the last week, with a monthly amount drifted -2.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on September 03, 2025, when RBC Capital Mkts upgraded its rating to a Outperform but kept the price target unchanged to $73 for it. Previously, Citigroup upgraded its rating to Buy on August 21, 2025, and kept the price target unchanged to $70. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on July 09, 2025. Wells Fargo initiated its recommendation with a Overweight and recommended $59 as its price target on May 30, 2025. KeyBanc Capital Markets downgraded its rating to Sector Weight for this stock on April 09, 2025. In a note dated March 18, 2025, Evercore ISI initiated an Outperform rating and provided a target price of $75 on this stock.
The stock price of Bio-Techne Corp [TECH] has been fluctuating between $46.01 and $80.95 over the past year. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $53.15 at the most recent close of the market. An investor can expect a potential return of 37.35% based on the average TECH price forecast.
Analyzing the TECH fundamentals
The Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.22B for trailing twelve months, representing a surge of 3.55%. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.04 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Bio-Techne Corp [NASDAQ:TECH]’s Current Ratio is 3.46. As well, the Quick Ratio is 2.38, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 6.78, the price to book ratio is 4.29 and price to earnings (TTM) ratio is 117.20.
Transactions by insiders
Recent insider trading involved Nusse Roeland, Director, that happened on Aug 25 ’25 when 17040.0 shares were sold. Director, BAUMGARTNER ROBERT V completed a deal on Aug 25 ’25 to sell 17040.0 shares. Meanwhile, Director ROELAND NUSSE bought 17040.0 shares on Aug 25 ’25.
